Radisavcevic, Djordje (57222992997)Djordje (57222992997)RadisavcevicDzamic, Zoran (6506981365)Zoran (6506981365)DzamicCico, Emre (57427651000)Emre (57427651000)CicoGrujicic, Sandra Sipetic (56676073300)Sandra Sipetic (56676073300)GrujicicMilojevicl, Bogomir (57428385900)Bogomir (57428385900)Milojevicl2025-06-122025-06-122021https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123512937&partnerID=40&md5=48580e40dbbd4796e00aba57aae85a2ehttps://remedy.med.bg.ac.rs/handle/123456789/4026Purpose: To evaluate the prognostic impact of ABO blood groups and Rhesus factor in patients with upper tract urothelial cancer (UTUC). Methods: The study included 78 consecutive patients who were treated with RNU. Demographic and clinicopathologic factors were analyzed using x2 or an unpaired t-test. Recurrence-free probabilities and cancer-specific (CSS) were estimated by the Kaplan-Meier method, and the log-rank test was used for the statistical differences. Univariate and multivariate Cox proportional hazard regression models were used to evaluate the association between various clinicopathologic factors with disease recurrence and CSS. Results: ABO blood groups antigen and Rhesus factor were not significantly associated with any clinicopathologic and patient characteristics. At a median follow up of 25.2 months, 42.3% of the patients experienced disease recurrence and 15.4% died of UTUC. History of bladder tumor (HR 1.34; 95% CI, 0.76-2.34; p=0.3) was associated with disease recurrence. ABO blood group (p=0.3) and Rhesus factor (HR 6.7; 95% CI, 0.76-59.2; p=0.08) were not independently associated with disease recurrence. There was no difference in CSS when we compared ABO blood groups and Rhesus factor. ABO blood group and Rhesus factor were not significantly associated with worse disease recurrence-free survival (p=0.4, log rank), (p=0.8, log rank) respectively. In addition, ABO blood group was not significantly associated with CSS (p=0.55), as well as Rhesus factor (p=0.3). Conclusions: ABO blood group antigens and Rhesus factor expression were unable to predict outcomes in a single-center series of consecutive patients who were treated with radical nephroureterectomy (RNU). © 2021 Zerbinis Publications. All rights reserved.ABO blood groupRadical nephroureterectomyRecurrenceRhesus factorUpper tract urothelial carcinoma